Ensysce Biosciences Inc (NASDAQ:ENSC) received an FDA Breakthrough Therapy Designation (BTD) for PF614-MPAR, a next-generation opioid. BTD has been granted to fewer than 300 drugs. It is designed to expedite the development and reviewing of drugs intended to treat a serious condition where preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapies. PF614-MPAR is designed to provide optimal pain relief at prescribed doses yet limit accid
Ensysce Biosciences Inc ENSC received an FDA Breakthrough Therapy Designation (BTD) for PF614-MPAR, a next-generation opioid. BTD has been granted to fewer…
Ensysce Biosciences breakthrough in opioid innovation! FDA grants PF614-MPAR BTD for enhanced pain relief with overdose protection. Learn more about this cutting-edge drug.
INVENTIVA: Inventiva announces the randomization of the first patient in China in the NATiV3 clinical trial and provides an update on its clinical development program finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.